83 results
8-K
EX-14.1
LRMR
Larimar Therapeutics Inc
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
is the responsibility of every employee, officer and director. Loss, theft and misuse of Company assets directly impact our profitability. Any suspected loss … a responsibility to provide full and accurate information, in all material respects, in our public disclosures about the Company’s financial condition and results
CORRESP
LRMR
Larimar Therapeutics Inc
16 Nov 18
Correspondence with SEC
12:00am
, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility
S-1
EX-10.13
LRMR
Larimar Therapeutics Inc
18 Apr 14
IPO registration
12:00am
applications and patents shall be the primary responsibility of CMCC in its sole discretion, except that Licensee shall have reasonable opportunities … applications or issued patent. Such notice shall not relieve Licensee from responsibility to reimburse CMCC for patent-related expenses incurred
10-K/A
2015 FY
LRMR
Larimar Therapeutics Inc
29 Apr 16
Annual report (amended)
12:00am
career, he was appointed to various positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery … leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within Biogen’s CNS commercial
8-K
LRMR
Larimar Therapeutics Inc
28 Feb 22
Results of Operations and Financial Condition
8:16am
of operations for the three months or year ended December 31, 2021. This estimate has been prepared by and is the responsibility of the Company’s management
8-K
imtlde di8
12 Feb 24
Results of Operations and Financial Condition
7:03am
424B5
5sxsrdiq8 2q
14 Sep 22
Prospectus supplement for primary offering
7:28am
8-K
EX-99.1
94f x2mdj8plr3qf0o
17 Jul 23
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
4:08pm
8-K
elmc795fui 71nw6ojp
30 Sep 15
Zafgen Announces Transition of Board of Directors
12:00am
424B5
7gp556
13 Feb 24
Prospectus supplement for primary offering
4:46pm
424B5
y3t22k8xe38jc3fvhq
14 Feb 24
Prospectus supplement for primary offering
5:08pm
8-K
EX-2.1
zm05 1hqwlui
9 Mar 20
Entry into a Material Definitive Agreement
12:00am
DEFA14A
EX-2.1
hmx0q4c0x9kp07
9 Mar 20
Additional proxy soliciting materials
12:00am
8-K
d0s sjojg029a
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
S-1
EX-3.3
be6ldjlvgsei ho
18 Apr 14
IPO registration
12:00am
8-K
EX-10.2
c3bife9osug9cm3xcfs
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am